Annual report
8129.TEDINET S100OLHO
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥1.21T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥1.26T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.22T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.21T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥4.3bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.3bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.7bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.0bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.1bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥10.3bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥16.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.4bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥5.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥683.2bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥670.8bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥663.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥645.8bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥445.8bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥237.4bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥231.0bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥213.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥207.8bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥93.1bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥90.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥80.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.4bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥63.7bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥13.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥52.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥680m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥680m | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥9.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥5.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.77 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥233.34 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.71 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.84 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.97 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥208.55 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥177.78 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥190.6 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥3,415.5 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,364.65 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,273.86 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,135.45 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,030.58 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.1% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 7,785 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 7,732 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 7,847 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 7,937 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 7,849 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥7.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥11.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥13.5bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥14.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥11.4bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥459m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥4.9bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥6.8bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.9bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥12.0bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥4.0bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥10.2bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.3bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥254.8bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥260.0bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥242.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥195.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥181.2bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥100.0bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥99.4bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥154.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥160.6bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥150.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥139.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥137.0bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥83.4bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥81.1bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥56.91 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.29 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.74 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥153.38 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.54 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥52.22 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥133.57 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥124.8 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.19 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.07 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,191.82 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,275.25 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,129.58 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,050.25 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,997.21 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.7% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.5% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 78,270,142 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 224 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 227 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 233 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 228 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 195 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | −¥9m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥56.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥56.5bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥89.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Dispensing Pharmacyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥444m |
| Dispensing Pharmacyreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥902m |
| Dispensing Pharmacyreportable segment | employees | at 2022-03-31 | 2468 pure |
| Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥91.8bn |
| Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥91.8bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥14m |
| Dispensing Pharmacyreportable segment | segment assets | at 2022-03-31 | ¥54.2bn |
| Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥3.0bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥126m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥180m |
| Medical Products Manufacturing And Salesreportable segment | employees | at 2022-03-31 | 98 pure |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥9.1bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥7.2bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2022-03-31 | ¥17.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥884m |
| Medical Products Retailreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.7bn |
| Medical Products Retailreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.6bn |
| Medical Products Retailreportable segment | employees | at 2022-03-31 | 4800 pure |
| Medical Products Retailreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.22T |
| Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥1.17T |
| Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥47.9bn |
| Medical Products Retailreportable segment | segment assets | at 2022-03-31 | ¥535.2bn |
| Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥4.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.32T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.27T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥56.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥612.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | −¥28m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥52.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥52.2bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥111.2bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥2.4bn |
| Dispensing Pharmacyreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥1.9bn |
| Dispensing Pharmacyreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥802m |
| Dispensing Pharmacyreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥91.1bn |
| Dispensing Pharmacyreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥91.1bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥8m |
| Dispensing Pharmacyreportable segment | segment assets | at 2021-03-31 | ¥53.2bn |
| Dispensing Pharmacyreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.7bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥132m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥8m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥8.1bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥5.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2021-03-31 | ¥5.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥729m |
| Medical Products Retailreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥4.0bn |
| Medical Products Retailreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥3.6bn |
| Medical Products Retailreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥1.16T |
| Medical Products Retailreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥1.12T |
| Medical Products Retailreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥46.0bn |
| Medical Products Retailreportable segment | segment assets | at 2021-03-31 | ¥511.3bn |
| Medical Products Retailreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥6.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥4.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥1.26T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥1.21T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥52.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥572.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥6.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,101
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 227 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 224 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 14 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 17 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 22 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 26 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 26 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.088 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.212 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.016 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.927 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.863 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.159 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.100 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.996 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.415 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.443 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02608-000MedicalProductsRetailReportableSegmentsMember | 4800 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02608-000MedicalProductsRetailReportableSegmentsMember | 1628 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02608-000DispensingPharmacyReportableSegmentsMember | 2468 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02608-000DispensingPharmacyReportableSegmentsMember | 666 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 98 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 29 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02608-000OtherRelatedBusinessMember | 195 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02608-000OtherRelatedBusinessMember | 11 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 224 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 26 | |
| Number of employees | CurrentYearInstant | 7785 | |
| Average number of temporary workers | CurrentYearInstant | 2360 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 224 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 26 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 47.4 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 18.6 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6049697 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 224 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 26 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 4480000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 78270142 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 78270142 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 78270142 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 78270142 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 22 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 17 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 99 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 200 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 7 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 4326 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 4671 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |